Education
About Us
Working with TipRanks
Follow Us
Assertio Therapeutics Inc (ASRT)
NASDAQ:ASRT
Earnings Data
Report Date
Nov 06, 2025Before Open (Confirmed)
Period Ending
2025 (Q3)Consensus EPS Forecast
-0.09Last Year’s EPS
-0.03Same Quarter Last Year
Strong Buy
Based on 3 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Neutral
The earnings call reflected a mix of positive developments such as strong demand for Rolvedon and successful legal settlements, but also faced challenges including a decline in net product sales and the discontinuation of Otrexup commercialization. The company's financial position remains strong, which supports future strategic transactions.Company Guidance
Strong Rolvedon Provider Demand
Rolvedon sales were $16.1 million, up from $15.1 million in the prior year quarter, driven by higher volume and favorability from returns reserve adjustment. Provider demand volume was the highest since launch, with a 20% increase from Q1 to Q2.
Sympazan Growth
Sympazan sales were $3.2 million, up from $2.7 million in the prior year period, reflecting higher volume and favorable payer mix. The company expects net sales to potentially double in the next several years.
Successful Legal Settlements
Assertio settled multiple legal matters, including the 2017 qui tam lawsuit and Glumetza antitrust action, reducing ongoing legal costs and business uncertainty.
Cash Position and Financial Flexibility
Cash, cash equivalents, and short-term investments totaled $98.2 million, an increase from $87.3 million as of March 31, 2025, driven by positive operating cash flows.
ASRT Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
ASRT Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Aug 11, 2025 | $0.72 | $0.82 | +13.89% |
May 12, 2025 | $0.62 | $0.61 | -1.61% |
Mar 12, 2025 | $0.78 | $0.72 | -7.69% |
Nov 11, 2024 | $0.92 | $0.85 | -7.61% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Assertio Therapeutics Inc (ASRT) report earnings?
Assertio Therapeutics Inc (ASRT) is schdueled to report earning on Nov 06, 2025, Before Open (Confirmed).
What is Assertio Therapeutics Inc (ASRT) earnings time?
Assertio Therapeutics Inc (ASRT) earnings time is at Nov 06, 2025, Before Open (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is ASRT EPS forecast?
ASRT EPS forecast for the fiscal quarter 2025 (Q3) is -0.09.